JARDIANCE®

Empagliflozin

 

Resources

Browse our engaging and informative collection of resources to learn more about JARDIANCE® (empagliflozin) for type 2 diabetes.

Quick links
View all
Upcoming event
Events

Explore upcoming stands and symposiums where Jardiance® will be present

View all
Quick links

Downloadable resources for healthcare professionals to support in the management of T2D patients

Downloadable patient booklets for healthcare professionals to offer to their patients

Video resources

These videos were developed, organised and funded by the Boehringer Ingelheim and Lilly Alliance.

Read more
Which patients may be suitable for empagliflozin treatment?
Video

Watch Dr Jarvis and Dr Javaid discuss which patients may be suitable for empagliflozin treatment.

February 2024
5:26 m

Watch now
Read more
The EMPA-REG OUTCOME trial: Participants and CV mortality outcome
Video

Watch Dr Jarvis and Dr Javaid discuss the EMPA-REG OUTCOME trial: participants and CV mortality outcome.

February 2024
4:26 m

Watch now
Read more
NICE guidance updates (NG28) and positioning of SGLT2 inhibitors
Video

Watch Dr Jarvis and Dr Javaid discuss NICE guidance updates (NG28) and the positioning of SGLT2 inhibitors.

September 2023
2:59 m

Watch now
 
Click here for JARDIANCE CKD resources
Click here for JARDIANCE CHF resources

PC-GB-108848 V4

June 2024

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.